Advertisement

Reactions Weekly

, Volume 1694, Issue 1, pp 21–21 | Cite as

Afatinib/erlotinib

Rash, paronychia and diarrhoea: 3 case reports
Case report

Reference

  1. Lewis PJ, et al. Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA). Lung Cancer 103 (Suppl. 1): S34 abstr. 71, Jan 2017 [abstract] - United KingdomGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations